1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Gaucher Disease - Pipeline Review, H1 2020, provides an overview of the Gaucher Disease (Genetic Disorders) pipeline landscape.
Gaucher disease is a rare genetic disorder occurs due to lacks an enzyme called glucocerebrosidase. Symptoms include cognitive impairment, enlarged spleen, severe swelling, lung disease, fatigue and seizures. Treatment includes enzyme replacement therapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Gaucher Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Gaucher Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gaucher Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Gaucher Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 6, 11 and 6 respectively. Similarly, the Universities portfolio in Phase I and Discovery stages comprises 1 and 5 molecules, respectively.
Gaucher Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gaucher Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Gaucher Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gaucher Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gaucher Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gaucher Disease (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gaucher Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gaucher Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Gaucher Disease - Overview
- Gaucher Disease - Therapeutics Development
- Gaucher Disease - Therapeutics Assessment
- Gaucher Disease - Companies Involved in Therapeutics Development
- Gaucher Disease - Drug Profiles
- Gaucher Disease - Dormant Projects
- Gaucher Disease - Discontinued Products
- Gaucher Disease - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Gaucher Disease, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Companies, H1 2020 (Contd..1), H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Gaucher Disease - Pipeline by Adienne Pharma & Biotech, H1 2020
- Gaucher Disease - Pipeline by Apollo Therapeutics LLC, H1 2020
- Gaucher Disease - Pipeline by AVROBIO Inc, H1 2020
- Gaucher Disease - Pipeline by Belrose Pharma Inc, H1 2020
- Gaucher Disease - Pipeline by Bioasis Technologies Inc, H1 2020
- Gaucher Disease - Pipeline by Biosidus SA, H1 2020
- Gaucher Disease - Pipeline by Blue Turtle Bio Technologies Inc, H1 2020
- Gaucher Disease - Pipeline by Erad Therapeutics Inc, H1 2020
- Gaucher Disease - Pipeline by Evox Therapeutics Ltd, H1 2020
- Gaucher Disease - Pipeline by Freeline Therapeutics Ltd, H1 2020
- Gaucher Disease - Pipeline by Generation Bio Co, H1 2020
- Gaucher Disease - Pipeline by Genzyme Corp, H1 2020
- Gaucher Disease - Pipeline by GT Gain Therapeutics SA, H1 2020
- Gaucher Disease - Pipeline by ILIAS Biologics Inc, H1 2020
- Gaucher Disease - Pipeline by ISU ABXIS Co Ltd, H1 2020
- Gaucher Disease - Pipeline by Johnson & Johnson, H1 2020
- Gaucher Disease - Pipeline by M6P Therapeutics, H1 2020
- Gaucher Disease - Pipeline by Orphazyme A/S, H1 2020
- Gaucher Disease - Pipeline by Prevail Therapeutics Inc, H1 2020
- Gaucher Disease - Pipeline by Sanofi, H1 2020
- Gaucher Disease - Pipeline by SmartPharm Therapeutics Inc, H1 2020
- Gaucher Disease - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020
- Gaucher Disease - Pipeline by Vera Therapeutics Inc, H1 2020
- Gaucher Disease - Pipeline by Yuhan Corp, H1 2020
- Gaucher Disease - Dormant Projects, H1 2020
- Gaucher Disease - Dormant Projects, H1 2020 (Contd..1), H1 2020
- Gaucher Disease - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Gaucher Disease, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Adienne Pharma & Biotech
- Apollo Therapeutics LLC
- AVROBIO Inc
- Belrose Pharma Inc
- Bioasis Technologies Inc
- Biosidus SA
- Blue Turtle Bio Technologies Inc
- Erad Therapeutics Inc
- Evox Therapeutics Ltd
- Freeline Therapeutics Ltd
- Generation Bio Co
- Genzyme Corp
- GT Gain Therapeutics SA
- ILIAS Biologics Inc
- ISU ABXIS Co Ltd
- Johnson & Johnson
- M6P Therapeutics
- Orphazyme A/S
- Prevail Therapeutics Inc
- Sanofi
- SmartPharm Therapeutics Inc
- Takeda Pharmaceutical Co Ltd
- Vera Therapeutics Inc
- Yuhan Corp
